Abstract 4046: Orally active PD-L1 inhibitor MAX-10181 in combination with temozolomide effectively prolonged survival in GBM animal model study

Yuguang Wang,Zhenhua Feng,Qiang Zhao,Wu Zhang,Yiwei Jiang,Yingqi Huang,Chenxing Qi,Cheng Zhang
DOI: https://doi.org/10.1158/1538-7445.am2024-4046
IF: 11.2
2024-03-24
Cancer Research
Abstract:Treatment of glioblastoma (GBM) with PD-1/PD-L1 immuno therapy is highly challenging due to the limited brain blood barrier (BBB) penetration of the marketed antibody drugs. During the past several years, we have successfully developed orally active, BBB penetrating, small molecule PD-L1 inhibitor MAX-10181 which is in the phase II clinical development. To demonstrate the utility of PD-1/L1 immuno therapy for the treatment of GBM, we completed the study of MAX-10181 in combination with Temozolomide (TMZ) in GL-261 animal model study. In this study, the combination of MAX-10181 with TMZ effectively prolonged the survival by 50% in comparison with TMZ single therapy. Details of this study will be reported in this meeting. Citation Format: Yuguang Wang, Zhenhua Feng, Qiang Zhao, Wu Zhang, Yiwei Jiang, Yingqi Huang, Chenxing Qi, Cheng Zhang. Orally active PD-L1 inhibitor MAX-10181 in combination with temozolomide effectively prolonged survival in GBM animal model study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4046.
oncology
What problem does this paper attempt to address?